KURA
vs
S&P 500
KURA
S&P 500
Over the past 12 months, KURA has underperformed S&P 500, delivering a return of +10% compared to the S&P 500's +14% growth.
Stocks Performance
KURA vs S&P 500
Performance Gap
KURA vs S&P 500
Performance By Year
KURA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Kura Oncology Inc
Glance View
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 121 full-time employees. The company went IPO on 2015-11-05. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. The company is developing its product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. The company is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The firm is developing orally available, small molecule compounds that inhibit the interaction between the proteins menin and MLL for the treatment of MLL-rearranged (MML-r) leukemias, a genetically-defined subset of approximately two forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic.
